Thailand Looks To Make Drug Pricing More Transparent
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Thailand will soon require pharmaceutical companies to be more transparent when reporting their costing structures as part of the registration process for new products, according to a resolution adopted by the country's first National Health Assembly on Universal Access to Essential Medicine in December
You may also be interested in...
Sanofi Asks Thailand To Review Compulsory Licensing Policy
Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.
GSK Pledge To Lower Drug Prices In Least-developed Countries To Have Minimal Impact In Asia
HONG KONG - GlaxoSmithKline's push to lower drug prices in the world's least-developed markets is not likely to have much of an impact for customers in larger and richer Asian markets but it could forestall competition from generic manufacturers
GSK Pledge To Lower Drug Prices In Least-developed Countries To Have Minimal Impact In Asia
HONG KONG - GlaxoSmithKline's push to lower drug prices in the world's least-developed markets is not likely to have much of an impact for customers in larger and richer Asian markets but it could forestall competition from generic manufacturers